Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

BioMarin Initiates Phase 3b Study to Evaluate the Effects of Kuvan on Neurophychiatric Symptoms in Subjects with PKU

August 17, 2010 By Bio-Medicine.Org

NOVATO, Calif., Aug. 17 /PRNewswire-FirstCall/ — BioMarin
Pharmaceutical Inc. (Nasdaq:
BMRN
) announced today that the first subject has initiated
treatment in a Phase 3b study (PKU-016) to evaluate the effects of
Kuvan (sapropterin dihydrochloride) on neuropsychiatric symptoms in
subjects with phenylketonuria (PKU).  BioMarin expects to
report results in the first half of 2012.

“We hope that this trial will provide quantitative data
regarding the neuropsychiatric effects of Kuvan for PKU patients,
and if successful, will continue to build its value proposition and
to drive the continued expansion of the market,” said Jean-Jacques
Bienaime, Chief Executive Officer of BioMarin. “Although we have
heard anecdotal accounts from patients and physicians regarding
Kuvan’s impact beyond blood Phe level reduction, BioMarin has never
formally evaluated these endpoints in a company trial due to the
extremely short development time for Kuvan.  We are excited to
have this important study underway, and if the results are
positive, we plan to file for a label amendment.  We also look
forward to upcoming data from several investigator-sponsored
studies on the neurocognitive effects of Kuvan at the SSIEM meeting
in Istanbul in late August.”

The Phase 3b study is a double-blind, placebo-controlled,
randomized 28-week study (2-week screening period, 13-week
randomized treatment period, 13-week open-label treatment period)
to evaluate the safety and therapeutic effects of sapropterin
dihydrochloride on neuropsychiatric symptoms in subjects with PKU.
 The study will enroll approximately 200 subjects ages twelve
and above at approximately 40 sites in the U.S. and Canada.
 

The primary efficacy variable for symptoms of attention deficit
hyperactivity disorder (ADHD) will be evaluated using the
Attention-Deficit Hyperactivity Disorder Rating Scale (ASRS) in
sub

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech